Aclaris Therapeutics (ACRS) Non Operating Income (2015 - 2026)
Aclaris Therapeutics (ACRS) posted quarterly Non Operating Income of $2.4 million for Q1 2026, down 21.04% year-over-year from $3.0 million in Q1 2025, and down 19.43% quarter-over-quarter from $2.9 million in Q4 2025.
Aclaris Therapeutics (ACRS) Non Operating Income (2015 - 2026) Analysis & Trends
Aclaris Therapeutics' Non Operating Income history runs 6 years deep, the most recent figure standing at $2.4 million for Q1 2026.
- In Q1 2026, Non Operating Income fell 21.04% year-over-year to $2.4 million; the TTM figure through Mar 2026 stood at $10.8 million (changed 0.5% YoY), while the FY2025 annual figure was $11.5 million, up 16.06% from the prior year.
- Non Operating Income for Q1 2026 stood at $2.4 million, down from $2.9 million in the prior quarter.
- The five-year high for Non Operating Income was $3.1 million in Q4 2024, with the low at $1.9 million in Q2 2024.
- The 4-year median for Non Operating Income is $2.5 million (2025), against an average of $2.6 million.
- The sharpest annual moves came in 2025 and 2026: Non Operating Income jumped 59.48% in 2025, then declined 21.04% in 2026.
- Aclaris Therapeutics' Non Operating Income stood at $2.2 million in 2023, then surged by 42.67% to $3.1 million in 2024, then decreased by 5.89% to $2.9 million in 2025, then decreased by 19.43% to $2.4 million in 2026.
- Business Quant data shows ACRS's Non Operating Income at $2.4 million in Q1 2026, $2.9 million in Q4 2025, and $2.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -139.24 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 12.40 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -51.63 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -53.64 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Aclaris Therapeutics | 808.18 Mn | 716.63 Mn | 1.41 Mn | 2.73 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.73 Mn |
| Mar 31, 2026 | 2.37 Mn |
| Dec 31, 2025 | 2.94 Mn |
| Sep 30, 2025 | 2.54 Mn |
| Jun 30, 2025 | 2.98 Mn |
| Mar 31, 2025 | 3.00 Mn |
| Dec 31, 2024 | 3.12 Mn |
| Sep 30, 2024 | 2.89 Mn |
| Jun 30, 2024 | 1.87 Mn |
| Mar 31, 2024 | 1.99 Mn |
| Dec 31, 2023 | 2.19 Mn |
| Sep 30, 2023 | 2.32 Mn |
| Sep 30, 2016 | 118,000.00 |
| Jun 30, 2016 | 118,000.00 |
| Mar 31, 2016 | 100,000.00 |
| Sep 30, 2015 | 8,000.00 |
| Jun 30, 2015 | 2,000.00 |
| Mar 31, 2015 | 6,000.00 |